Does Medicare Cover GLP-1?

Summary: Medicare Part D covers GLP-1 drugs for type 2 diabetes, covers Wegovy for cardiovascular risk reduction since the March 2024 CMS memo, and starting July 1, 2026 covers Wegovy, Zepbound KwikPen, and Foundayo for weight loss at a flat $50 copay under the short-term GLP-1 Bridge demonstration.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: it depends on why the drug is being prescribed. Medicare Part D covers GLP-1 medications when they are prescribed for type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza). It covers Wegovy for cardiovascular risk reduction in adults with established CV disease since the March 20, 2024 CMS memo ^[1]. It covers Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. And starting July 1, 2026, the new Medicare GLP-1 Bridge demonstration covers Wegovy, the Zepbound KwikPen, and Foundayo for weight loss at a flat $50 monthly copay ^[2].

What Medicare still does not cover, as ordinary Part D benefit, is a GLP-1 prescribed for weight loss alone. That coverage runs through the Bridge demonstration, not through your Part D plan.

The historical exclusion: why this is complicated

Part D was created by the Medicare Modernization Act of 2003. The statute, codified at 42 U.S.C. 1395w-102(e)(2)(A), inherited a list of drug categories Part D plans were prohibited from covering. One of those categories was "agents when used for anorexia, weight loss, or weight gain." That single phrase is the reason every conversation about GLP-1s and Medicare for the past five years has been about how to work around it.

The exclusion was written into law in an era when "weight-loss drugs" meant phentermine and amphetamine derivatives with poor safety profiles. Congress saw weight-loss pharmacotherapy as cosmetic and excluded it. The language never anticipated drugs like semaglutide and tirzepatide, which produce 15 to 25 percent weight reductions and clear downstream reductions in cardiovascular events, sleep apnea severity, and kidney disease progression.

When Wegovy was approved for chronic weight management in 2021 and Zepbound followed in 2023, Medicare beneficiaries learned the answer to "does Medicare cover this for weight loss?" was no, statutorily, no matter how obese they were or how many comorbidities they had.

The March 2024 CMS carve-out for Wegovy

The first crack in the wall was the SELECT trial. Novo Nordisk ran a 17,604-patient randomized trial of semaglutide 2.4 mg versus placebo in adults with established cardiovascular disease and a BMI of 27 or greater, without diabetes. The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. SELECT reported a 20 percent relative reduction in MACE over a mean 39.8 months of follow-up ^[3].

On March 8, 2024, the FDA approved a new indication for Wegovy: to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established CV disease and either obesity or overweight. Twelve days later, on March 20, 2024, CMS issued a Part D coverage memo confirming that anti-obesity medications with a separate FDA-approved indication that is not weight loss can be covered under Part D for that medically accepted indication ^[1].

The memo's logic: the statutory exclusion bars Part D coverage of agents "used for" weight loss. When Wegovy is prescribed for CV risk reduction in a patient with established CV disease, it is not "used for" weight loss. It is used for the FDA-approved cardiovascular indication, and Part D plans may cover it for that purpose.

The practical effect was immediate. Part D plans, including standalone PDPs and Medicare Advantage plans with drug coverage, could now add Wegovy to formularies for the CV indication. They were not required to. Coverage varies plan to plan, almost always sits on a non-preferred specialty tier, and almost always requires prior authorization documenting the established CV disease.

The 2024 Zepbound sleep apnea expansion

The same logic applied again in December 2024 when the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. Part D plans could then cover Zepbound for OSA, since OSA is a medically accepted indication that is not weight loss ^[4].

So as of 2025, three GLP-1 coverage pathways existed under Part D:

That last row is what the Medicare GLP-1 Bridge changes.

The Medicare GLP-1 Bridge: $50 copay, July 2026 to December 2027

On December 23, 2025, CMS announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a five-year demonstration designed to waive the weight-loss exclusion and let Part D plans cover GLP-1 medications for obesity. BALANCE was scheduled to launch in Medicare in 2027. Insufficient Part D plan sign-ups by the April 2026 deadline caused CMS to delay BALANCE for Medicare beneficiaries ^[2].

In its place, CMS launched the short-term Medicare GLP-1 Bridge, which begins July 1, 2026 and runs through December 31, 2027. The Bridge operates outside the Part D benefit and uses Humana as the central processor for prior authorization, claims, and pharmacy payment ^[2].

What the Bridge covers: Wegovy (injection and tablets, all formulations), Zepbound KwikPen (single-dose vials and single-dose pens are excluded), and Foundayo (all formulations), when prescribed for weight management ^[2].

Who qualifies, per the CMS prior authorization criteria at therapy initiation:

• Age 18 or older AND BMI greater than or equal to 35, OR
• Age 18 or older AND BMI greater than or equal to 30 with diastolic heart failure (HFpEF), uncontrolled hypertension on two antihypertensives, or chronic kidney disease stage 3a or higher, OR
• Age 18 or older AND BMI greater than or equal to 27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease ^[2].

The beneficiary must be enrolled in a standalone Part D plan or a Medicare Advantage plan that includes Part D, and must be participating in lifestyle modification including structured nutrition and physical activity.

The Bridge ends December 31, 2027. What happens after that is unsettled. If BALANCE launches for Medicare in 2028, weight-loss GLP-1s would shift back inside the Part D benefit. If it does not, the statutory exclusion reasserts itself.

Diabetes coverage: the path that has always worked

For Medicare beneficiaries with type 2 diabetes, GLP-1 coverage has been straightforward for years. Ozempic, Rybelsus, Mounjaro, Trulicity, and Victoza are all FDA-approved for type 2 diabetes and are covered under Part D for that indication. Coverage specifics depend on the plan formulary, but almost all Part D plans cover at least one or two GLP-1s in the diabetes class.

What "covered" looks like in practice:

• The drug sits on a non-preferred brand tier (Tier 3) or a specialty tier (Tier 4 or 5).
• Prior authorization is almost universal. The PA requires documentation of a type 2 diabetes diagnosis and, on many plans, a trial of metformin first unless contraindicated.
• Copays vary by plan and by deductible phase. After the deductible, a Tier 3 brand GLP-1 commonly runs $40 to $100 a month. On a specialty tier with coinsurance, the patient pays a percentage of the drug's negotiated price.
• Quantity limits are typical. Plans cap fills at one pen or one month's supply per fill.

Mounjaro and Ozempic are the two GLP-1s most often approved for T2D patients under Medicare. If a plan does not cover the specific drug your endocrinologist wants, the formulary exception process is available, and a peer-to-peer review with the plan's medical director sometimes overturns the initial denial.

The Drug Price Negotiation Program: Ozempic, Rybelsus, Wegovy in 2027

The Inflation Reduction Act gave CMS authority to negotiate prices for selected high-spend Part D drugs. CMS announced in early 2025 that Ozempic, Rybelsus, and Wegovy were selected together as a single negotiation product for initial price applicability year 2027. The maximum fair price for that semaglutide bundle takes effect January 1, 2027 ^[2].

The negotiated price applies only to Part D-covered uses (diabetes for Ozempic and Rybelsus, CV risk reduction for Wegovy). It does not apply to the GLP-1 Bridge in 2026. The 2027 interaction between the negotiated price and the Bridge is still being defined.

State Medicaid: highly variable, mostly weight-loss-excluded

Medicaid is administered state by state. Unlike Medicare Part D, Medicaid does not face a statutory exclusion of weight-loss drugs at the federal level. States may cover obesity pharmacotherapy in their Medicaid programs, and a slow but growing minority do.

As of mid-2026, roughly a dozen state Medicaid programs cover Wegovy or Zepbound for obesity, almost always with strict prior authorization criteria (high BMI thresholds, comorbidity requirements, documented prior weight-loss attempts, lifestyle program participation). The largest state Medicaid programs that cover GLP-1s for weight loss include California (Medi-Cal), Pennsylvania, Massachusetts, and Virginia. Many other states cover GLP-1s only for type 2 diabetes ^[5].

If you are under 65 and on Medicaid, the answer to "does Medicaid cover GLP-1?" depends entirely on which state you live in and what your diagnosis is. Call your state Medicaid pharmacy benefits line or check the preferred drug list (PDL) on your state's Medicaid website.

CMS announced that the BALANCE Model is still proceeding for state Medicaid agencies that want to participate, even though the Medicare side is on hold. State Medicaid programs that opt into BALANCE will have federal support to cover GLP-1s for obesity for the duration of the demonstration ^[2].

What other coverage paths look like

Medicare beneficiaries with secondary coverage sometimes have additional options.

• Veterans (VA pharmacy benefit). The Department of Veterans Affairs added Wegovy to its national formulary in 2024 for veterans meeting specific BMI and comorbidity criteria. Zepbound has been added in more limited fashion. Veterans dual-eligible for Medicare and VA can often fill GLP-1 prescriptions through VA pharmacies at lower cost than through Part D.
• TRICARE. For active-duty and retired military beneficiaries, TRICARE covers GLP-1s for type 2 diabetes. TRICARE for Life beneficiaries (Medicare-eligible retirees) receive TRICARE as secondary to Medicare; Wegovy and Zepbound coverage for weight loss has historically been limited but has expanded somewhat.
• Employer retiree plans. Many large employers maintain post-65 retiree health coverage that wraps around Medicare. These plans sometimes cover weight-loss GLP-1s where standard Part D does not. Check your retiree plan's formulary.
• Medigap. Medigap (Medicare Supplement) does not cover prescription drugs. It only covers Part A and Part B cost-sharing. Medigap is irrelevant to GLP-1 coverage.

How to navigate the system in 2026

If you are on Medicare and want a GLP-1 drug, the path depends on why you want it.

For type 2 diabetes:

1. Talk to your prescriber. Confirm the diabetes diagnosis is documented in your chart with ICD-10 code E11.
2. Check your Part D plan's formulary. Most plans cover Ozempic or Mounjaro for diabetes.
3. Expect a prior authorization. The PA will ask for HbA1c values, current diabetes regimen, and documentation that you have tried metformin or have a contraindication.
4. Fill at an in-network pharmacy. Specialty drugs sometimes require mail-order through the plan's preferred specialty pharmacy.

For weight loss alone, starting July 1, 2026:

1. Confirm you meet the Bridge clinical criteria (BMI thresholds plus optional comorbidities, see above).
2. Ask your prescriber to submit the prior authorization request directly to the central processor (Humana), not to your Part D plan. The Bridge BIN/PCN is 028918 / MEDDGLP1BR ^[2].
3. Confirm your pharmacy is set up to process Bridge claims. CMS is rolling out pharmacy guidance through Spring and Summer 2026.
4. Pay the $50 copay at the counter. Save your pharmacy receipts.
5. Document your participation in a lifestyle modification program. CMS will be issuing additional guidance on what counts.

For Wegovy for cardiovascular risk reduction:

1. Document established CV disease in the chart (prior MI, prior stroke, prior coronary revascularization, symptomatic PAD, etc.) and overweight or obesity status.
2. Have your prescriber submit the standard Part D prior authorization to your plan with the CV indication.
3. If the plan denies, file a Part D coverage determination request, then an appeal if needed. Cite the March 2024 CMS memo ^[1].

What to do if you are denied

A Part D denial is not the end of the road. The appeals process is structured, defined in 42 CFR Part 423 Subpart M.

1. Coverage determination request. Your prescriber submits an exception request explaining the medical necessity. The plan has 72 hours to respond (24 hours for expedited).
2. Redetermination (level 1 appeal). If denied, request redetermination within 60 days. Plan has 7 days to respond.
3. Independent review entity (level 2). A CMS contractor independent of the plan reviews. 7 days for standard, 72 hours for expedited.
4. Administrative law judge (level 3). For claims over a dollar threshold ($190 in 2026).
5. Medicare Appeals Council (level 4).
6. Federal district court (level 5).

Most successful appeals win at level 1 or level 2. The keys: a complete medical record, a detailed letter of medical necessity from the prescriber citing FDA-approved indications and clinical guidelines, and documentation that alternatives have been tried or are contraindicated.

Bridge denials follow a separate process. CMS has indicated the Bridge does not modify Part D appeal rights, so if a Part D plan denies a Wegovy claim that should have been routed to the Bridge, you can appeal through Part D channels and request a redirection to the central processor ^[2].

Self-pay and discount paths if Medicare does not work

If you do not meet Bridge criteria, your Part D plan denies your prior authorization, and you cannot afford the full cash price, several options exist outside the Medicare benefit:

• Eli Lilly direct (LillyDirect). Lilly sells Zepbound vials at $349 to $499 per month direct to consumers without insurance, depending on dose.
• Novo Nordisk direct (NovoCare). Novo offers Wegovy at a comparable direct-pay price.
• TrumpRx and other direct-to-consumer discount programs. TrumpRx links to manufacturer-direct prices that have ranged from $199 to $699 per month depending on drug and dose.
• HSA and FSA dollars. If you have a health savings account (rare for Medicare beneficiaries) or were carrying a balance from pre-Medicare years, GLP-1 prescriptions for an FDA-approved indication are qualified medical expenses.
• Patient assistance programs. Both Novo Nordisk and Eli Lilly run income-based patient assistance programs that can provide medication at low or no cost for qualifying patients. The income thresholds are typically 400 to 500 percent of the federal poverty level.

Telehealth programs that compound semaglutide or tirzepatide outside the FDA shortage list operate in a contested legal space and are not recommended as a long-term sourcing strategy.

Frequently asked questions about Medicare and GLP-1 drugs

Does Medicare cover Ozempic?

Yes, for type 2 diabetes, on most Part D plans, typically with prior authorization and a non-preferred brand or specialty tier copay. Not for weight loss.

Does Medicare cover Wegovy for weight loss?

Not under standard Part D. Wegovy is covered under Part D for cardiovascular risk reduction in adults with established CV disease (per the March 2024 CMS memo). Starting July 1, 2026, Wegovy is also covered for weight loss under the GLP-1 Bridge demonstration at a $50 copay for qualifying beneficiaries.

Does Medicare cover Zepbound?

For moderate-to-severe obstructive sleep apnea in adults with obesity, yes under Part D since the December 2024 FDA approval. For weight loss alone, only under the GLP-1 Bridge starting July 2026, and only the KwikPen formulation.

Does Medicare cover Mounjaro?

Yes, for type 2 diabetes on most Part D plans with prior authorization. Mounjaro is not eligible for the GLP-1 Bridge because Mounjaro is FDA-approved only for diabetes, not for weight loss (Zepbound is the weight-loss-approved version of tirzepatide).

Does Medicaid cover GLP-1 drugs?

For type 2 diabetes, yes in nearly every state Medicaid program. For weight loss, only in roughly a dozen states as of 2026. Coverage is highly state-specific. Check your state's Medicaid preferred drug list.

Does Cigna cover GLP-1?

Cigna commercial plans typically cover Ozempic and Mounjaro for type 2 diabetes with prior authorization. Wegovy and Zepbound coverage varies by employer group and depends on whether the employer purchased a weight-loss drug rider.

Does Aetna cover GLP-1?

Aetna commercial coverage for GLP-1s mirrors Cigna's pattern: diabetes coverage is broad, weight-loss coverage depends on the employer's plan design. Aetna Medicare Advantage plans follow Part D rules.

Does Blue Cross Blue Shield cover GLP-1 medications?

BCBS is a federation of independent licensees, so coverage varies by state and by employer. For diabetes, coverage is standard. For weight loss, many BCBS plans cover Wegovy and Zepbound but with strict prior authorization criteria including BMI thresholds and prior lifestyle intervention documentation.

Does Kaiser Permanente cover GLP-1 medications?

Kaiser's integrated model covers GLP-1s for diabetes and (in some regions and plans) for weight loss, generally through Kaiser pharmacies after PA. Kaiser Senior Advantage (Medicare Advantage) follows Part D rules plus the GLP-1 Bridge for weight loss.

Does TRICARE cover GLP-1?

Yes for type 2 diabetes (Ozempic, Mounjaro, Trulicity covered with PA). Wegovy and Zepbound for weight loss have been added on a limited basis. TRICARE for Life beneficiaries should also check their primary Medicare Part D plan.

Does the VA cover GLP-1 for veterans?

The VA national formulary includes Wegovy for veterans meeting BMI and comorbidity criteria, and limited tirzepatide coverage. Dual-eligible veterans often get better pricing through VA than through Part D.

What is COBRA and does it help with GLP-1 coverage?

COBRA lets you continue your former employer's health plan for up to 18 months after job loss. Whether COBRA covers a GLP-1 depends on what the underlying employer plan covered. COBRA premiums are full cost plus 2 percent, so it is usually only worth keeping if you already have an active prior authorization in place.

What does GLP-1 prior authorization require?

For diabetes: a documented T2D diagnosis (HbA1c values, ICD-10 E11), often a prior trial of metformin, and the prescribing physician's attestation. For weight loss under the Bridge: BMI documentation at the time of GLP-1 therapy initiation, qualifying comorbidities if BMI is under 35, and lifestyle modification participation. For Wegovy CV indication: documented established cardiovascular disease.

What happens if my prior authorization is denied?

File a coverage determination request, then a redetermination (level 1 appeal), then an Independent Review Entity appeal (level 2). Most appeals that succeed do so at level 1 or 2 with a detailed letter of medical necessity. Cite the relevant FDA indication and the March 2024 CMS memo if denied for Wegovy CV use.

Can I use HSA or FSA for GLP-1 medications?

Yes for any FDA-approved indication, since GLP-1 prescriptions are qualified medical expenses under IRS guidance. Most Medicare beneficiaries do not have active HSAs (Medicare enrollment disqualifies new HSA contributions), but existing HSA balances can still be spent.

How do I get a GLP-1 if I am uninsured?

Eli Lilly's LillyDirect ($349 to $499 for Zepbound vials), Novo Nordisk's NovoCare for Wegovy, TrumpRx for manufacturer-direct pricing, or patient assistance programs for low-income patients. Cash prices for brand pens at retail pharmacies are typically $900 to $1,400 a month without negotiation.

Are international pharmacy GLP-1 options legal?

Importing prescription drugs from foreign pharmacies is technically illegal under FDA rules, though enforcement against individuals for personal-use quantities has historically been rare. Canadian and UK pharmacy prices for Ozempic and Wegovy can be 40 to 60 percent below US cash prices, but quality, authenticity, and customs seizure risks are real concerns.

How do I avoid running out of a GLP-1?

Refill 5 to 7 days before your supply ends, not the day of. Keep one spare pen if your plan allows. If your prior authorization renewal is approaching, have your prescriber submit the renewal 30 days before expiration. During shortages, your pharmacy can order ahead if you give notice.

What does the Endocrine Society say about GLP-1 use?

Endocrine Society clinical guidelines support GLP-1 use for type 2 diabetes (often as second-line after metformin or first-line in patients with established CV disease) and for obesity in adults meeting BMI and comorbidity criteria. The 2024 obesity pharmacotherapy guideline reflects the strong evidence base from SURMOUNT, STEP, and SELECT trials.

What comes next

The Medicare GLP-1 Bridge ends December 31, 2027. CMS has signaled that the BALANCE Model could launch for Medicare in 2028 if enough Part D plans sign on. If BALANCE does launch, weight-loss GLP-1 coverage would move back into the standard Part D benefit, with plans bearing the cost rather than CMS funding it directly through a demonstration.

If BALANCE does not launch, the 2003 statutory exclusion reasserts itself and weight-loss GLP-1 coverage under Medicare disappears again unless Congress acts. The Treat and Reduce Obesity Act (TROA) has been introduced in multiple sessions of Congress and would amend the Part D statute to permit weight-loss drug coverage. It has not passed.

For now, the practical answer to "does Medicare cover GLP-1?" is: yes for diabetes, yes for the CV indication of Wegovy, yes for the OSA indication of Zepbound, and yes for weight loss between July 2026 and December 2027 through the Bridge at $50 a month for qualifying beneficiaries. Outside those lanes, it is cash pay.